Relapsed Multiple Myeloma Clinical Trial
Official title:
An Open-Label Phase I Trial to Evaluate the Safety and Tolerability of ATRA, Celecoxib, and Itraconazole Administered As Maintenance Treatment Post-Autologous Transplantation in Relapsed Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability associated with the combination of ATRA/celecoxib/itraconazole as maintenance therapy given after an autologous stem cell transplant in relapsed multiple myeloma patients.
Primary objective:
To evaluate safety and tolerability associated with the combination of ATRA/
celecoxib/itraconazole given after a salvage transplant for relapsed myeloma in 25 patients
in a cycle schedule consisting of three weeks of treatment followed by a rest period of two
weeks for a total of five cycles. Subjects will be evaluable only if they have received at
least one dose of maintenance treatment. The salvage transplant is not part of this study.
Secondary objective:
To explore changes in frequency and molecular signature in the multiple myeloma stem cell
(MMSC) fraction based on flow-cytometric assays and gene expression profiling before and
after the experimental treatment and to correlate outcome with expression levels of RARĪ±2 at
time of relapse.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04083534 -
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06119685 -
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05577000 -
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01118689 -
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
|
Phase 1 | |
| Withdrawn |
NCT04802031 -
Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT00603447 -
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
|
Phase 1 | |
| Active, not recruiting |
NCT02722668 -
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
|
Phase 2 | |
| Active, not recruiting |
NCT04965155 -
A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)
|
Phase 2 | |
| Completed |
NCT00592579 -
A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma
|
Phase 2 | |
| Not yet recruiting |
NCT06433947 -
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT06304636 -
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT03158688 -
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
|
Phase 3 | |
| Completed |
NCT04434469 -
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01080391 -
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
|
Phase 3 | |
| Not yet recruiting |
NCT06348108 -
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01949532 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
|
Phase 1 | |
| Active, not recruiting |
NCT04398485 -
A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT03091933 -
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
|
Phase 1/Phase 2 | |
| Completed |
NCT01272466 -
Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05896228 -
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 2 |